Integrated Advisors Network LLC Invests $4.73 Million in TransMedics Group, Inc. $TMDX

Integrated Advisors Network LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the first quarter, Holdings Channel.com reports. The fund bought 47,590 shares of the company’s stock, valued at approximately $4,731,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group in the third quarter worth about $29,000. Allworth Financial LP lifted its holdings in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. Parallel Advisors LLC boosted its position in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after acquiring an additional 83 shares in the last quarter. Ascentis Independent Advisors bought a new stake in TransMedics Group during the 1st quarter valued at approximately $30,000. Finally, North Star Investment Management Corp. bought a new stake in TransMedics Group during the 1st quarter valued at approximately $30,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of several research reports. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Canaccord Genuity Group restated a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Piper Sandler decreased their price objective on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Finally, TD Cowen reissued a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research report on Wednesday, July 1st. Six investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $134.50.

Insider Transactions at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

TransMedics Group Stock Down 3.0%

TransMedics Group stock traded down $2.11 during mid-day trading on Tuesday, hitting $69.12. The company had a trading volume of 247,539 shares, compared to its average volume of 1,103,368. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a market capitalization of $2.39 billion, a PE ratio of 15.75 and a beta of 1.89. The stock’s 50 day moving average price is $74.20 and its two-hundred day moving average price is $107.75. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. TransMedics Group’s revenue was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.70 earnings per share. As a group, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.92 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.